GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial

GSK’s head of vaccine R&D, Phil Dormitzer, M.D., Ph.D., can almost taste regulatory success as the company soon approaches an FDA deadline for a decision on its respiratory syncytial virus (RSV) vaccine in older adults. If approved, it could become the first in the world.